Table of Contents
PLAINSBORO, N.J. –Novo Nordisk announced Monday updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month. Until today, the $499-per-month offer for Wegovy was only available via the recently launched NovoCare Pharmacy.
"At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them accessible to and affordable for the communities we serve," said Dave Moore, Executive Vice President, U.S. Operations and Global Business Development and President of Novo Nordisk Inc. "With the evolution of our Wegovy savings program, we continue to deliver options that empower people living with obesity to more easily pursue their weight management and health goals."
Beyond NovoCare Pharmacy, the Wegovy savings program offers another avenue for people living with obesity to ensure they are receiving authentic, FDA-approved Wegovy® from reputable pharmacies, helping to avoid the significant risks that can be posed by the compounding marketplace, as warned by respected organizations, experts in the medical community, and the FDA. With an FDA-approved medicine like Wegovy, healthcare professionals and patients can have clarity and confidence in knowing the medicine they are using has undergone rigorous review for safety, effectiveness, and quality. Patients can get the savings offer and find more information at Wegovy.com.
